drugset / Trial / NCT05346783

Comparing Efficacy and Safety of TJO-083 in Dry Eye Disease Patients

NCT05346783

Phase 1/2 Unknown 98 enrolled Taejoon Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a prospective randomized study compared with active control and placebo arms.

Timeline

Start
2021-10-14
Primary completion
2022-12
Completion
2023-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Diquafosol Oligonucleotide (other) 3 % Other
Subject TJO-083 Unknown Other

Indications